Why is Akums Drugs falling/rising?

As of 20-Oct, Akums Drugs & Pharmaceuticals Ltd is experiencing a price increase, currently at 467.40, reflecting a rise of 6.75 or 1.47%. Today's performance indicates that the stock has outperformed its sector by 0.79% and has shown a trend reversal after two consecutive days of decline. However, despite this short-term gain, the stock has underperformed over the past month with a return of -1.93% compared to a 2.10% increase in the benchmark. The stock has also faced significant challenges over the past year, with a staggering decline of -48.58% while the benchmark has gained 3.86%. The company maintains a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 2.4, alongside a notable increase in profits by 1362%, which may support the recent price movement.
Broader market context shows that while Akums Drugs has seen a slight uptick in the short term, its long-term performance remains concerning, with poor growth metrics such as a net sales growth rate of only 6.10% over the last five years. The stock's recent performance is juxtaposed against a backdrop of declining investor participation, as evidenced by a significant drop in delivery volume. Furthermore, the company reported a flat PAT in the latest quarter, with a notable decline in operating profit relative to interest expenses, indicating ongoing financial pressures. Overall, while there is a temporary rise in the stock price, the broader context suggests persistent challenges that could hinder sustained growth.